Yunxia Gao

Yunxia Gao

Auto-generated profile, based on publicly available information

Yunxia Gao

Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2022 in Eye
Verified
Journal Article
Closed access
PDF file
XRXiang Ren
Xiang Ren
WFWei Feng
Wei Feng
RRRuijin Ran
Ruijin Ran
YGYunxia Gao
Yunxia Gao
YLYu Lin
Yu Lin
MZMing Zhang
Ming Zhang

11 April 2023 in Eye
Verified
Journal Article
Open access
PDF file
YGYunxia Gao
Yunxia Gao
FLFang Lu
Fang Lu
XLXiaoxin Li
Xiaoxin Li
HDHong Dai
Hong Dai
KLKun Liu
Kun Liu
MZMing Zhang
Ming Zhang
Objective: To evaluate the efficacy and safety of oral vorolanib for the treatment of neovascular (wet) age-related macular degeneration (nAMD). Methods: In the dose escalation, participants received ascending doses of oral vorolanib (25–100 mg daily). In the dose expansion, participants received recommended doses (25 and 50 mg daily). Results: Between March 15, 2015, and January 23, 2019, 41 participants were enrolled in 6 centres in China. At the data cut-off (November 14, 2019), two dose-limiting toxicities (DLTs) were observed during dose escalation (one in the 75 mg cohort and one in the 100 mg cohort). The maximum tolerated dose was not reached. Treatment-related adverse events (TRAEs) occurred in 33 (80.5%) participants, and grade 3 or higher TRAEs occurred in 12 (29.3%) participants. No fatal TRAEs were observed. Increases in the mean best-corrected visual acuity (BCVA) from baseline to Day 360 of +7.7 letters (range, −5–29; n = 41) were observed in participants who were administered vorolanib. Corresponding reductions in mean central subfield thickness (CST) and choroidal neovascularization (CNV) area at Day 360 were observed in these three groups. Conclusions: Oral administration of vorolanib improved visual outcomes in participants with nAMD with manageable systemic safety profiles.

12 December 2022 in Eye
Verified
Journal Article
Open access
PDF file
YGYunxia Gao
Yunxia Gao
XRXiang Ren
Xiang Ren
HLHong Lin
Hong Lin
KLKang Li
Kang Li
LXLirong Xiao
Lirong Xiao
MZMing Zhang
Ming Zhang
Purpose In this study, we described a large family presenting different manifestations of cone dystrophy at different ages associated with GUCY2D gene mutation. Method Sixty-three individuals of a single kindred, including 23 affected with cone dystrophies, were recruited and received ocular examinations, including best corrected visual acuity, intraocular pressure, slit-lamp biomicroscopy, color fundus photograph (CFP), fundus autofluorescence, optical coherence tomography, fluorescence fundus angiography, color vision testing, full-field electroretinography, and electro-oculogram. Whole exome sequencing (WES) and Sanger sequencing were performed for underlying mutations associated with cone dystrophy. Result There were 23 affected family members. Clinical analysis showed that the proband and other patients had impaired visual acuity ranging from 20/800 to 20/50 with impaired color vision. Fundus photograph showed retinal pigment epithelium (RPE) granular abnormalities with depressed macular reflex in young patients and macular or retinochoriodal atrophy in older patients. OCT examination confirmed the reduced outer retinal thickness or inner retinal thickness, absence of the ellipsoid zone (EZ) and retinal atrophy to varying degrees. Electroretinography revealed a reduced cone response combined with a relatively maintained rod response. WES and Sanger sequencing revealed a heterozygous variant c.2512C>T in the GUCY2D gene of the affected family members. Conclusions We reported cone dystrophy in 23 affected individuals in a five-generation family and demonstrated different macular abnormalities in OCT scans and CFP at different ages. The multimodal ocular records in our study provide physicians and ophthalmologists with a better understanding of cone dystrophy associated with GUCY2D mutation.